The Royal Marsden, a renowned cancer center, is pioneering Online Adaptive Radiation Therapy (OART) with RaySearch’s advanced technology. Supported by The Royal Marsden Cancer Charity, the center aims to implement the ARTemis solution, developed collaboratively with Accuray. This initiative represents a significant leap forward in radiotherapy, enabling real-time adaptation of treatment plans based on daily patient images. With the expertise of The Royal Marsden, coupled with innovative technology from RaySearch and Accuray, this endeavor promises to revolutionize cancer care worldwide.
The Royal Marsden NHS Foundation Trust stands at the forefront of cancer research and treatment, continually striving to push the boundaries of innovation. With a legacy of excellence spanning decades, the center has embraced cutting-edge technologies to enhance patient outcomes. Now, with the support of The Royal Marsden Cancer Charity, The Royal Marsden is poised to make history as the first center in the world to implement Online Adaptive Radiation Therapy (OART) utilizing RaySearch’s groundbreaking ARTemis solution. This introduction explores the significance of this initiative in advancing the field of radiotherapy and its potential impact on cancer treatment.
Having utilized RayStation for conventional treatment planning since 2016, The Royal Marsden is renowned for its commitment to advancing radiotherapy research both nationally and globally. With recent support from The Royal Marsden Cancer Charity, the center has procured two additional Radixact treatment delivery machines from Accuray, specifically with the intent of employing them for OART.
OART represents a significant advancement in radiotherapy, leveraging daily patient images to dynamically optimize treatment plans based on real-time changes in patient anatomy while they are on the treatment couch. However, implementing OART necessitates seamless coordination between the treatment planning system, oncology information system, and treatment control system, alongside high-quality images acquired by the delivery machine.
ARTemis, a collaborative endeavor between RaySearch and Accuray, aims to address these challenges by providing a comprehensive online adaptive solution. This solution will integrate RayStation’s automated adaptive replanning capabilities, RayCare’s robust clinical workflow management tools, and Accuray’s ClearRT imaging technology to enable optimized online adaptive therapy.
The Royal Marsden, located in Sutton, is set to adopt the complete ARTemis package, with funding support from The Royal Marsden Cancer Charity. The center aims to lead the way as the first facility worldwide to routinely administer OART to patients treated on the Radixact System.
Professor Uwe Oelfke, Head of the Joint Department of Physics at The Royal Marsden and The Institute of Cancer Research, London, expressed pride in the center’s pioneering role, stating, “We are proud that The Royal Marsden will be the first in the world to provide this unique technology thanks to funding from The Royal Marsden Cancer Charity. The ARTemis platform will enable us to tailor treatment in real time for patients being treated on our two new Radixact machines, which are due to be installed in 2024 and 2025, allowing us to target their disease more precisely and reduce damage to healthy tissue. We look forward to developing this exciting new service with valued support from RaySearch and Accuray.”
Johan Löf, founder and CEO of RaySearch, echoed Professor Oelfke’s sentiments, highlighting the clinical benefits of adaptive radiation therapy and the potential of ARTemis to revolutionize patient care. He expressed gratitude for the partnership with The Royal Marsden, a collaboration that promises to drive innovation in radiotherapy and improve outcomes for patients.
Overall, The Royal Marsden’s pioneering efforts in Online Adaptive Radiation Therapy (OART) signify a monumental advancement in cancer care. With the support of RaySearch, Accuray, and The Royal Marsden Cancer Charity, the center is spearheading a transformative approach to radiotherapy. By leveraging real-time adaptation of treatment plans through the ARTemis solution, The Royal Marsden is poised to enhance precision and efficacy in cancer treatment, ultimately improving outcomes for patients worldwide. This groundbreaking collaboration sets a new standard for innovation in radiotherapy and underscores The Royal Marsden’s commitment to excellence in cancer care.
